Effect of comorbidities on response to pulmonary rehabilitation in patients with chronic obstructive pulmonary disease  by Hassan, Maged et al.
Egyptian Journal of Chest Diseases and Tuberculosis (2016) 65, 63–69HO ST E D  BY
The Egyptian Society of Chest Diseases and Tuberculosis
Egyptian Journal of Chest Diseases and Tuberculosis
www.elsevier.com/locate/ejcdt
www.sciencedirect.comORIGINAL ARTICLEEﬀect of comorbidities on response to pulmonary
rehabilitation in patients with chronic obstructive
pulmonary disease* Corresponding author at: Chest Diseases Department, Faculty of Medicine, 21521 Azarita, Alexandria, Egypt. Tel.: +20 1118292111
E-mail address: nashwahassan65@yahoo.com (N.H. Abdel Wahab).
Peer review under responsibility of The Egyptian Society of Chest Diseases and Tuberculosis.
http://dx.doi.org/10.1016/j.ejcdt.2015.11.006
0422-7638  2015 The Authors. Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest Diseases and Tube
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Maged Hassan a, Sahar Mourad a, Nashwa Hassan Abdel Wahab a,*, Rasha Daabis a,
Gihan Younis baDepartment of Chest Diseases, Faculty of Medicine, Alexandria University, Egypt
bDepartment of Physical Medicine, Rheumatology & Rehabilitation, Faculty of Medicine, Alexandria University, EgyptReceived 14 July 2015; accepted 10 November 2015




ComorbidityAbstract Background and objective: Patients with chronic obstructive pulmonary disease (COPD)
typically manifest with worsening dyspnea, poor exercise tolerance and diminished quality of life. In
addition, comorbidities are commonly reported in these patients, complicating management strate-
gies. Pulmonary rehabilitation (PR) is an evidence-based multimodality therapy increasingly pre-
scribed for symptomatic COPD patients. This study aimed to assess the impact of comorbidities
on achieving proper response to PR in patients with COPD.
Methods: Forty patients with COPD were enrolled in PR program of upper and lower extremity
exercise, and were prospectively followed. The minimal clinically important difference (MCID) was
used as a cut-off to determine response in six-minute walk distance (6MWD), modified Medical
Research Council (mMRC) dyspnea scale, Saint George Respiratory Questionnaire (SGRQ) and
estimated maximum oxygen consumption (VO2max). According to comorbidities patients were
divided into three groups: patients without comorbidities, patients with one comorbidity and
patients with more than one comorbidity.
Results: Comorbidities were diagnosed in 34 patients (85%). Patients with one or more comor-
bidity had significantly worse baseline mMRC, 6MWD, SGRQ score and VO2max but not FEV1%.
Thirty-two patients (80%) showed improvements beyond the MCID. Factors that predicted better
response included higher arterial PaCO2, presence of osteoporosis, and lower baseline 6MWD,
mMRC and VO2max.
Conclusions: Pulmonary rehabilitation can be offered to COPD patients from different severity
stages. Comorbidities occur very commonly in patients with COPD and their presence worsens the.
rculosis.
64 M. Hassan et al.baseline functional status in these patients which makes them more liable to achieve larger
benefits from PR.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest
Diseases and Tuberculosis. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Chronic obstructive pulmonary disease (COPD) is one of the
most prevalent diseases in the world [1]. It afflicts around 1%
of the global population and its prevalence rises steeply after
the age of 40 [2]. The hallmark of COPD is progressive airflow
limitation secondary to noxious stimuli, the most important of
which is tobacco smoke. This is manifested as progressively
worsening dyspnea and poor exercise tolerance [3].
Pathologically, COPD involves chronic inflammation of the
lung, particularly in peripheral airways and parenchyma and
this inflammation increases during acute exacerbations [4].
Inflammation is not only a pulmonary problem in COPD,
but it has been demonstrated that systemic inflammation is a
constant feature in the disease [5]. This diffuse inflammatory
state is thought to be due to spill over from the lungs and is
responsible for the systemic manifestations of COPD. Systemic
inflammation is arguably a contributory factor in the develop-
ment of several of the comorbidities of COPD or at least leads
to its worsening [5].
Pulmonary rehabilitation (PR) is a cornerstone of manage-
ment of COPD that aims to improve physical well-being while
enhancing disease management. In addition to exercise train-
ing of lower and upper extremities, the core component of
PR, it also incorporates patient education and behavioral
change [6]. It is recognized that there is some heterogeneity
in response to PR between individuals, with some people not
achieving meaningful improvement [7]. Some researchers have
striven to gauge the effect of comorbidities on response to PR
[8–11]. While some of them noted a negative effect with some
comorbidities, [9,11] others have not reported such findings
[8,10].
This study aimed to evaluate the impact of baseline func-
tional status as well as common comorbidities on the effect
of PR on COPD patients.
Methods
Patients
Patients with COPD who presented to the outpatient clinic
with acute exacerbation were offered PR after stabilization
of the condition. Comorbidities were observed at the baseline
as well as the physiologic and functional status of the patients.
Patients were prospectively followed for response to PR
according to previously set criteria. Diagnosis of COPD was
confirmed by post bronchodilator spirometry and classifica-
tion was based on the most recent guidelines of the global
strategy for chronic obstructive pulmonary disease (GOLD)
[3]. Patients with uncompensated respiratory acidosis, history
of previous lung surgery, acute heart failure, disabling neuro-
muscular conditions, ischemic heart disease and cognitive
impairment were excluded from the study.Comorbidities were recorded based on the patients direct
questioning, patients’ medication list and specific diagnostic
tests for certain comorbidities. According to the presence or
absence of comorbidities as well as its frequency, patients were
divided into three groups. The first group was assigned for
patients who had no comorbidities with COPD. The second
group was dedicated for patients suffering from one comorbid-
ity and the third group included patients with more than one
comorbidity.
Pulmonary rehabilitation
All patients underwent PR program with optimization of
pharmacological therapy and/or long term oxygen therapy
according to standard guidelines. Exercise training targeted
upper and lower extremity muscles. For lower extremity, aero-
bic exercise on treadmill was done. The applied method of
training was interval training; 3 min of exercise alternating
with 3 min of rest and intensity of training was targeted to
reach 60–80% of maximal heart rate but was modified accord-
ing to patient’s tolerance. Upper extremity exercise was in the
form of repetitive lifting of free weights. Thirty repetitions
were performed of weights that were determined according
to patient’s tolerance. Increased weights were used by the start
of each new week. The training program ran for 8 weeks, 3 ses-
sions per week under supervision. In addition, patients’ educa-
tion wad done, including instructions for disease self-
management (prevention and early treatment of exacerbations,
breathing strategies and bronchial hygiene techniques) [6].
Outcome measurement
The following physiological/functional parameters were
recorded for all patients at the baseline and at the end of the
program. Airway obstruction was measured by post-
bronchodilator spirometry.
Functional exercise capacity was assessed using the six-
minute walk distance (6MWD) performed according to Amer-
ican Thoracic Society guidelines [12]. Dyspnea was assessed by
the modified Medical Research Council (mMRC) scale [13].
Quality of life was gauged via St. George’s Respiratory Ques-
tionnaire (SGRQ) [14]. Aerobic capacity was estimated by cal-
culating maximum oxygen consumption (VO2max) via the
modified Rockport walking test (RWT) [15]. The formula used
to calculate the VO2max was:
132:853 ð0:0769WeightÞ  ð0:3877AgeÞ þ ð6:315
GenderÞ  ð3:2649 TimeÞ  ð0:1565Heart rateÞ
where weight is in pounds; gender is coded as Male = 1 and
Female = 0; time is expressed in minutes and 100th of a
minute and it refers to time taken to complete 400 m or till
reaching degree of fatigue; maximum heart rate is in beats/
minute and age is in years.
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(MCID) to determine response to PR was used [16]. Improve-
ments were determined by the following cut-off points: exercise
capacity [+30 m in the 6MWD], [17] dyspnea [1 point on the
mMRC dyspnea scale] [18] and health status [4 points on the
SGRQ] [19]. For FEV1%, the MCID was set as change by
7.5% [20]. We calculated the MCID for aerobic capacity
(VO2max) using the distribution method, which determines
the MCID for a specific test as 0.5 standard deviation (SD)
of the variable in the studied population [20]. One SD for
VO2max was 19 ml/kg/min and thus the MCID following PR
was decided as increase by 9.5 ml/kg/min.
Statistical analysis
All statistical analyses were performed using PASW software
(version 17; SPSS Inc., Chicago, IL, USA). All results were
considered statistically significant at p< 0.05. Quantitative
variables were presented as mean ± SD. Means for parametric
variables were compared by student T-test or ANOVA accord-
ing to situation. Non parametric quantitative variables were
compared by Mann–Whitney test and Kruskal–Wallis test
according to situation. Qualitative variables were presented
as frequencies and comparisons were made by Chi square test.
A comparison was made between the three comorbidity
groups according to baseline demographic, clinical and physi-
ologic parameters. The comparison of physiologic parameters
was repeated after concluding the PR program. The group of
responders was then compared with the non-responders and
variables that showed significant difference were entered into
logistic regression.
Results
This study recruited 55 patients to undergo PR. Fifteen
patients did not complete the program either due to lack of
perceived benefit or problems with transportation. Data of
patients who dropped out were not included. Thirty-four
patients (85%) had comorbidities. Fig. 1 demonstrates the
frequencies of the recorded comorbidities. Cardiovascular
disease included systemic hypertension, cor pulmonale,Figure 1 Bar chart comparing frequencies of dicerebro-vascular stroke and valvular heart disease. Metabolic
disorders comprised diabetes mellitus and dyslipidemia.
Accordingly patients were divided into three groups based
on comorbidities as shown in Fig. 2. A comparison between
the comorbidity groups according to baseline characteristics
is shown in Table 1. Patients with one comorbidity were signif-
icantly younger than patients without comorbidities (data not
shown). Bone mineral density (BMD) was significantly lower
among patients with comorbidities. Most patients (36)
belonged to stage D according to the new GOLD classifica-
tion. Except for FEV1%, all other functional parameters were
significantly different between groups (Table 1) and consis-
tently worse for patients with more than one comorbidity (data
not shown). After completion of the PR program, the compar-
ison between groups according to functional parameters was
repeated (Table 2). Again except for FEV1%, the mean values
for functional parameters have improved in all comorbidity
groups, but the inter-group differences have become statistically
insignificant (Table 2). By applying the MCID for mMRC,
6MWD, SRGQ and VO2max the number of patients who
achieved these preset values was 32 (80%). Table 3 demon-
strates a comparison between responders (32) and non-
responders (8) according to baseline characteristics as well as
the frequency of different comorbidities. Responders had signif-
icantly higher values of PaCO2, baseline mMRC score and
SGRQ score and lower values of baseline 6MWD and VO2max
(Table 3). When these variables were entered into regression
model to predict response to PR, none of them stood the test
of significance, likely due to the relatively small sample size.
Discussion
The present study strove to observe the prevalence of comor-
bidities in patients with COPD and to evaluate whether base-
line physiological and functional characteristics as well as
specific comorbidities may predict a poorer response to PR.
Diagnosis of COPD was done according to the more-
inclusive new staging system proposed by GOLD [3] that
depends not only on the severity of airflow limitation but also
on the degree of dyspnea and the frequency of occurrence of
exacerbations. Previous studies in the same subject reliedfferent comorbidities among studied patients.
Figure 2 Pie chart demonstrating sizes of the three study groups.
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eration the degree of air obstruction only [8–10,21]. The major-
ity of our patients (90%) belonged to group D underscoring
the fact that this cohort of patients was symptomatic and fre-
quently experienced exacerbations.
Comorbidities were highly prevalent in the studied cohort
and occurred in 34 patients (85%). Similarly high proportions
were reported in previous studies, ranging between 50% and
98.5% [8–10,21]. In one of the largest studies addressing the
topic of comorbidities and COPD, Divo et al. [22] reportedTable 1 Anthropometric, demographic and functional characteristi
mean ± SD for continuous variables and frequencies for categorical
All patients Comorbidity gro
0
Age years 60.38 ± 8.9 68.17 ± 8.1
Males/females n 37/3 6/0
PYI pack years 59.34 ± 27.9 37.5 ± 11.3
BMI kg m2 24.24 ± 5 24.78 ± 3.9
LTOT n 10 (25%) 0
pH 7.41 + 0.06 7.43 ± 0.02
PaCO2 mmHg 40.8 ± 8.1 39 ± 2.5
PaO2 mmHg 72.4 ± 14 82.3 ± 17





FEV1% 32.1 ± 11 35.9 ± 7
mMRC 2.78 ± 0.83 2 ± 0.63
6MWD meters 183 ± 83.5 253 ± 85.7
SGRQ % 71 ± 15.5 57.21 ± 18.9
VO2max ml/kg/min 39.5 ± 19 52.3 ± 7.5
SD, standard deviation; PYI, pack year index; BMI, body mass index; LT
global strategy for chronic obstructive pulmonary disease; PaCO2, partial
oxygen; FEV1, forced expiratory volume in one second; mMRC, modifie
distance; SGRQ, Saint George Respiratory Questionnaire; VO2max, max
Bold = significant at p value < 0.05.
* ANOVA.
y Chi-square.
 Kruskal–Wallis.that in their cohort of 1664 patients, the average number of
comorbidities was 6 + 3.5 per subject for the whole cohort.
It is no wonder that patients with severer forms of COPD
commonly report comorbidities as both the severity of the dis-
eases and the systemic manifestations/comorbidities have cau-
sal link to systemic inflammation [5].
The most prevalent comorbidities in our cohort (cardiovas-
cular disease in 40% of patients and osteoporosis in 35%) have
been linked to systemic inflammation in COPD patients. Sys-
temic inflammation observed in COPD is chiefly responsible
for pulmonary and systemic endothelial dysfunction [23]. Also
this intense inflammation in addition to hypoxia and protease/
antiprotease imbalance have all been found to be contributory
to the development of osteoporosis in the advanced stages of
COPD [24].
The cohort of patients with comorbidities tended to be
younger than COPD patients without any comorbidity
(Table 1). There was no statistically significant difference in
the smoking index between comorbidity groups to account
for this age difference. Whether the presence of comorbidities
predisposes patients with COPD to be symptomatic at an ear-
lier age is a question that needs further investigation in future
research.
In the studied patients, the presence of comorbidities signif-
icantly affected the values of 6MWD, mMRC and SGRQ, and
VO2max. Patients without comorbidities, when compared to the
other two groups, tended to have less dyspnea, better quality
of life and more exercise tolerance.
The worsened functional and symptomatic status of




57.79 ± 8.5 60.53 ± 8.4 0.041*
17/2 14/1 0.686y
65.37 ± 33.7 61.7 ± 21.12 0.069
23.22 ± 4.08 25.3 ± 6.4 0.483*
5 5 0.276y
7.42 ± 0.04 7.40 ± 0.09 0.707*
40.16 ± 10 42.47 ± 6.8 0.635*
72.53 ± 11.8 68.4 ± 14.23 0.173*





32.24 ± 11 30.42 ± 11.9 0.600*
2.56 ± 0.89 3.22 ± 0.54 0.007
192 ± 84.5 143.6 ± 61 0.040
69.76 ± 16.4 78.15 ± 7.88 0.014*
41.28 ± 19.8 30.23 ± 18.9 0.045
OT, long term oxygen therapy; BMD, bone mineral density; GOLD,
pressure of arterial carbon dioxide; PaO2, partial pressure of arterial
d Medical Research Council dyspnea scale; 6MWD, six minute walk
imum oxygen consumption.
Table 2 Outcome measures at the end of program among comorbidity groups. Data are presented as mean ± SD.
All patients Comorbidity groups p-value
0 1 >1
FEV1% 31.8 ± 10.1 36 ± 8 31.38 ± 10.4 30.75 ± 10.8 0.556
*
mMRC 1.33 ± 0.8 0.83 ± 0.98 1.21 ± 0.97 1.67 ± 0.61 0.111y
6MWD meters 338.7 ± 106 371.7 ± 144 364.7 ± 102 292.7 ± 82 0.101y
SGRQ % 48 ± 14.3 41.9 ± 17 46.5 ± 16.3 52.4 ± 9.4 0.266*
VO2max ml/kg/min 60 ± 11.9 61.1 ± 13.8 64 ± 9.57 54.48 ± 11.9 0.068
y
SD, standard deviation; FEV1, forced expiratory volume in one second; mMRC, modified Medical Research Council dyspnea scale; 6MWD, six
minute walk distance; SGRQ, Saint George Respiratory Questionnaire; VO2max, maximum oxygen consumption.
* ANOVA.
y Kruskal–Wallis.
Table 3 Comparison between responders and non-responders
to pulmonary rehabilitation according to baseline anthropo-
metric, physiologic, clinical and functional parameters. Data
are presented as mean ± SD for continuous variables and






Age years 59.2 ± 8.69 65 ± 8.86 0.127*
Sex male/female 29/3 8/0 0.368
PYI pack years 60.67 ± 28.85 54.38 ± 25.27 0.665y
GOLD B/C/D 1/1/30 1/1/6 0.287
LTOT n 9 1 0.361
pH 7.42 ± 0.04 7.39 ± 0.12 0.482*
PCO2 mmHg 41.8 ± 8.61 37 + 3.92 0.028
*
PO2 mmHg 70.5 ± 13.31 80.3 ± 15.46 0.133
*
BMD SD 2.26 ± 0.55 1.58 ± 0.75 0.058*
BMI kg m2 23.8 ± 5.12 25.9 ± 4.71 0.300*
Cachexia 8 0 0.114
CV disease 12 4 0.519
Osteoporosis 14 0 0.020
Metabolic disease 8 3 0.479
Bronchiectasis 5 1 0.232




167.5 ± 81.59 246.1 ± 61.27 0.012y
Baseline
VO2max ml/min
35.82 ± 19.38 54.51 ± 6.33 0.007y
Baseline mMRC 2.94 ± 0.75 2.13 ± 0.83 0.019y
Baseline SGRQ 72.86 ± 14.40 63.66 ± 18.82 0.228*
0 Comorbidity 3 3 0.068
1 Comorbidity 12 3 0.872
>1 Comorbidity 17 2 0.204
SD, standard deviation; PYI, pack year index; GOLD, global
strategy for chronic obstructive pulmonary disease; BMI, body
mass index; LTOT, long term oxygen therapy; PaCO2, partial
pressure of arterial carbon dioxide; PaO2, partial pressure of arte-
rial oxygen; BMD, bone mineral density; FEV1, forced expiratory
volume in one second; mMRC, modified Medical Research Council
dyspnea scale; 6MWD, six minute walk distance; SGRQ, Saint
George Respiratory Questionnaire; VO2max, maximum oxygen
consumption.
Bold = significant at p value < 0.05.
* Independent T test.
y Mann–Whitney test.
 Chi-square test.
Effect of comorbidities on response to pulmonary rehabilitation 67previous studies. Even after accounting for differences in age,
sex and smoking history, COPD patients with comorbidities,in particular cardiovascular disease and DM, were found to
be generally more dyspneic and had a reduced exercise capac-
ity in comparison to patients without comorbidities [25]. The
presence of three or more comorbid diseases in COPD was
found to be more predictive of decreased health status than
any demographic or clinical variable [26].
The presence of these comorbid conditions worsens the feel-
ing of dyspnea on exertion which predisposes patients to lead a
sedentary life. Deconditioning is thus, at least, partially respon-
sible for the poorer functional status of patients with comor-
bidities. Skeletal myopathy and metabolic abnormalities
noted in chronic diseases that are much similar to changes
noted in COPD are also responsible for such poor status [27].
The PR program was offered to patients during convales-
cence from acute exacerbation. This choice was based on a sys-
tematic review conducted by Puhan and colleagues of clinical
trials studying PR in COPD patients following acute exacerba-
tions [28]. It demonstrated a significant reduction in the odds
of hospital admission, in addition to large consistent improve-
ments in the SGRQ total score, and the domain scores for
activity limitation and impact [28].
Examining the values of measurements of assessments at
the end of program for the three comorbidity groups, the pre-
viously noted inter-group wide differences in 6MWD, VO2max,
mMRC and SQRG have narrowed after PR. These findings
might serve to prove that the severer impairment noted in
COPD patients who have comorbidities in comparison to
patients without comorbidities is modifiable rather than per-
manent. Breaking the vicious circle of deconditioning that
causes exercise limitation uncovered a considerably better
potential to perform effort than what was apparent initially.
Determining response to PR in each patient relied on the
concept of MCID which provides a guide as to whether an
intervention provides a minimum level of perceived benefit
and transcends the concept of statistical differences [20].
The overall improvement after PR was noted in 80% of
patients, which is in accordance with the findings of previous
studies who reported response rates of >50% [6].
Drawing a comparison between responders and non-
responders, there were significant differences in baseline
PaCO2, 6MWD, VO2max, mMRC and frequency of osteoporo-
sis where responders always had the worse levels. Crisafulli
et al. [8] found that higher values of PaCO2 were associated
with better outcome after PR. The same researchers also con-
cluded that the worse the baseline condition (lower 6MWD or
higher mMRC) was, the more likely it was that the patient
68 M. Hassan et al.responded well to PR. They argued that a degree of improve-
ment less than the MCID in patients with a better baseline
condition could be due to a ‘‘ceiling effect” [8]. These findings
inform us that inclusion of patients with poorer physical per-
formance and lower gas exchange capacity corresponds to a
more elevated probability of improving their functional status.
It is certainly noteworthy that this study did not find that
the presence of one or more comorbidities had negative effect
on the response to PR. Earlier research [9] has provided a com-
pletely different view, where the impact of comorbidities was
reported to inversely predict the improvement of both exercise
tolerance and QoL after PR. More recent research (by the
same investigator) found results similar to the present study
and concluded that individual comorbidities (either alone or
in combination) did not preclude indication and/or effective-
ness of a PR course [8].
Study limitation
The formula of modified RWT to estimate VO2max was used.
The present study has found this formula to be inaccurate in
estimating the values of VO2max, mostly over-estimating the
results (when compared to expected values according to age).
It was used, nonetheless, as a rough guide to the changes that
occurred in each patient. Cardiopulmonary exercise testing
would be recommended as a much more accurate tool. The
small number of non-responders to PR imposed considerable
hindrance to performing regression analysis to find the vari-
ables that could predict a negative response to PR. This limi-
tation might have been solved with a larger patient sample.
Conclusions
Comorbidities commonly associate COPD and they worsen
the functional and physiologic impairments seen in these
patients. Patients with comorbidities demonstrate better
response to exercise training in the context of PR when com-
pared with patients without comorbidities and thus the pres-
ence of comorbidities should encourage the inclusion of
patients with COPD to PR. Future research will need to verify
the factors that can predict poor response to PR. Another
question that deserves answering is whether PR by itself can
have effect, either positive or negative, on comorbidities in
patients with COPD.
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